國藥科技股份(08156.HK)附屬以發行代價股份方式收購香港中醫診所集團母公司40%股權 作價4160萬港元
格隆匯12月13日丨國藥科技股份(08156.HK)公佈,於12月12日,買方眾彩企業管理有限公司(公司的一間全資附屬公司)與賣方訂立股權轉讓協議,據此,賣方出售而買方購入相當於目標公司永衍控股有限公司40%股權的目標股份,代價為4160萬港元,公司根據一般授權按每股代價股份0.23港元發行價向賣方以配發及發行代價股份的方式支付。代價股份相當於(i)公司於截至公告日期已發行股本約4.40%;及(ii)經擴大後公司已發行股本約4.22%。
公告顯示,每股代價股份0.23港元較收市價每股股份0.22港元溢價約4.5%。
根據股權轉讓協議,賣方已向買方擔保及承諾,截至2020年12月31日及2021年12月31日止年度各年的經審核税後淨利潤將不得少於1300萬港元或截至2021年12月31日止兩個年度的經審核税後淨利潤合共不得少於2600萬港元。
據悉,目標公司為於BVI註冊成立的投資控股公司。目標公司持有健福堂100%股權。
健福堂為香港最大型連鎖現代化中醫診所集團之一。健福堂透過轄下4個不同品牌(包括「健福堂」、「黃祥華」、「港專醫療」及「CardiaxLab」),為客人提供一站式全方位醫療及健康服務。於公告日,健福堂在香港經營19家現代化中醫診所,其中包括3間享有佛山馳名品牌「黃祥華」名下中醫診所,透過望聞問切,為客人提供全面臨牀中醫服務。
此外,健福堂同時於中環蘭桂坊經營一所旗艦智能心臟檢測管理中心「CardiaxLab」,該中心引入並採用美國FDA認證設備及技術,為客人提供專業可靠、全面且非入侵性心血管診斷和管理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.